Search Results

You are looking at 101 - 110 of 377 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017

William G. Wierda, Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Paolo Caimi, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Michael G. Martin, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Erin D. Snyder, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Mary A. Dwyer, and Hema Sundar

statistically significant survival benefit compared with FC in patients aged <65 years (5-year OS, 80.9% and 69.2%, respectively; P =.002); corresponding 5-year OS rates were 73.9% and 61.6%, respectively ( P =.288). The incidence of prolonged neutropenia was

Full access

Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2− Breast Cancer

included Table 1. CDK 4/6 Inhibitors neutropenia, anemia, and fatigue. No cases of febrile neutropenia were observed. However, an increased rate of grade 3/4 infections and pulmonary embolism was seen in the palbociclib/letrozole arm (5% vs 0

Full access

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Seema Bhat, Greg Bociek, Danielle Brander, Jennifer Brown, Asher Chanan-Khan, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Jeffrey Lancet, Shuo Ma, Sami Malek, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Andrew D. Zelenetz, Mary A. Dwyer, and Hema Sundar

study. The most common treatment-related toxicities were neutropenia (grade 3/4; 20%) and infections (any grade; 53%), including those requiring intravenous antibiotics (27%). In a study of 358 patients with untreated HCL, cladribine resulted in a CR

Full access

Emerging Therapies in the Treatment of Bladder Cancer

Presented by: Arlene O. Siefker-Radtke

govitecan may experience side effects. Neutropenia, including febrile neutropenia, and diarrhea, nausea, and vomiting were among the most frequently reported treatment-related adverse events in the study population. 10 “Patients with bladder cancer, in

Full access

Pertuzumab in the Treatment of HER2+ Breast Cancer

Komal Jhaveri and Francisco J. Esteva

neutropenia were noted in 2 of 2 patients treated with 75 mg/m 2 of docetaxel and 1050 mg of pertuzumab every 3 weeks. Of 5 patients, 2 who received 100 mg/m 2 of docetaxel and 420 mg of pertuzumab (after a loading dose of 840 mg) every 3 weeks experienced

Full access

Evolving Paradigms in the Treatment of Newly Diagnosed Multiple Myeloma

Alessandra Larocca and Antonio Palumbo

very good partial response (VGPR) were particularly higher with RD, as was 1-year PFS. However, this improvement did not translate into an overall survival advantage. The incidences of grade 3/4 neutropenia (21% vs. 5%) and thromboembolic events (24% vs

Full access

New NCCN Guidelines: Cancer Management in People Living With HIV

Gita Suneja

, vinblastine, and dacarbazine) is recommended for treating HL in people with HIV infection. However, dose reductions may be required for prolonged severe neutropenia. 7 In this population, growth factors may be required for those with a low CD4-positive T

Full access

Optimizing Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Presented by: Anthony Mato

differences in atrial fibrillation favoring zanubrutinib over ibrutinib (10.1% vs 2.5%), although neutropenia occurred more frequently in patients receiving zanubrutinib. Hypertension was the same with either agent. The ELEVATE-RR trial, which compared

Full access

Correspondence

Marc Fishman, William Shimp, James Krook, Akhil Kumar, and William J.M. Hrushesky

alternative choices but rather avoiding use of the drug with chemotherapy regimens with a low risk of febrile neutropenia. 2 , 3 We agree with Dr. Burstein that a serious dialogue on cost-effective care is needed. Talk, however, is clearly not enough. We

Full access

The Top Five in Oncology: Where Do We Go From Here?

Harold J. Burstein

. No white cell–stimulating factors for primary prevention of febrile neutropenia for patients with less than 20% risk for this complication. If the ancient adage, “First, do no harm” is still sacred, then the next line would be “Second, do no